Please input keywords

YH010 is a potentially first-in-class fully human PD-L1 x IL12 bispecific antibody for the treatment of solid tumors. YH010 simultaneously activates the IL12 signaling pathway while inhibiting PD-L1 binding to PD-1. YH010 also has the potential to further enhance the specific killing activity of T cells by tethering IL12R positive T cells with PD-L1 positive tumor cells.
naver-site-verification: naver8a6b0412e3d2d9dd38f1684b831435ac.html